- The U.S. Department of Defense office of Congressionally Directed Medical Research Programs Joint Warfighter Medical Research Program awards a contract to Cleveland BioLabs (CBLI +5.7%) valued at up to $9.2M to support the continued development of entolimod as a medical radiation countermeasure.
-
Entolimod is a recombinant protein that acts as an agonist of toll-like receptor 5 (TLR5), an innate immunity receptor. It is being developed under the FDA's Animal Rule guidance which permits the approval of a drug based on animal studies when human efficacy studies are not possible. The DoD contract will fund the pivotal animal studies that will support a BLA submission.